Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00751348
Other study ID # 110876
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 1, 2008
Est. completion date May 27, 2010

Study information

Verified date May 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.


Recruitment information / eligibility

Status Completed
Enrollment 475
Est. completion date May 27, 2010
Est. primary completion date May 27, 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 11 Months to 24 Months
Eligibility Inclusion Criteria:

- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.

- A male or female between, and including 11 and 24 months of age, at the time of the vaccination.

- Written informed consent obtained from the parent or guardian of the subject.

- Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.

- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.

- Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period.

- Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days prior to until 42 days after the study vaccine dose with the exception of inactivated vaccines such as pneumococcal, Haemophilus influenzae type b conjugate vaccines, inactivated influenza, hepatitis A or B vaccine or diphtheria/tetanus-containing vaccines which can be administered up to eight days before the study vaccine dose.

- Previous vaccination against measles, mumps, rubella and/or varicella.

- History of measles, mumps, rubella and/or varicella/zoster diseases.

- Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to study start.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

- A family history of congenital or hereditary immunodeficiency.

- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including systemic hypersensitivity to neomycin.

- Major congenital defects or serious chronic illness.

- Acute disease at the time of enrolment.

- Rectal temperature = 38°C or axillary temperature = 37.5°C at the time of vaccination.

- Residence in the same household as a high risk person e.g.:

- New-born infants (0-4 weeks of age)

- Pregnant women who have a negative history of chickenpox

- Persons with known immunodeficiency

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
PriorixTM
Subcutaneous administration in left upper arm
VarilrixTM
Subcutaneous administration in right upper arm
Priorix-Tetra®
Subcutaneous injection in left upper arm

Locations

Country Name City State
Korea, Republic of GSK Investigational Site Bucheon-si,
Korea, Republic of GSK Investigational Site Daejeon
Korea, Republic of GSK Investigational Site Gwangju
Korea, Republic of GSK Investigational Site GyeongSangNam-do
Korea, Republic of GSK Investigational Site Iksan
Korea, Republic of GSK Investigational Site Incheon
Korea, Republic of GSK Investigational Site Jeonju Jeonbuk
Korea, Republic of GSK Investigational Site Seongnam-si, Gyeonggi-do
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Uijeongbu, Kyonggi-do
Korea, Republic of GSK Investigational Site Wonju-si Kangwon-do

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (1)

Sung-Ho Cha et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella (MMRV) vaccine: an open-labeled, randomized trial in healthy Korean children. Abstract presented at the Fall Meeting of Korean Vaccine Society (KVS). Seoul, Korea, 31 August 2013.

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Zoster Virus (VZV) Antibodies Above the Cut-off Values Seroconversion was defined as the appearance of antibodies [i.e. titer greater than or equal to (=) the cut-off value] in the sera of subjects seronegative [i.e. titer below (<) cut-off value] before vaccination. Cut-off values were the following: Anti-measles concentration = 150 milli-international units per milliliter (mIU/mL); Anti-mumps concentration = 231 units per milliliter (U/mL); Anti-rubella concentration = 4 international units per milliliter (IU/mL); Anti-VZV titer = 1:4 dilution. At 42 days post-vaccination
Secondary Antibody Concentrations Against Measles Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL). At 42-days post-vaccination
Secondary Antibody Concentrations Against Mumps Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in units per milliliter (U/mL). At 42-days post-vaccination
Secondary Antibody Concentrations Against Rubella Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL). At 42-days post-vaccination
Secondary Antibody Titers Against Varicela Viruses Antibody titers were presented as geometric mean titers (GMTs). At 42-days post-vaccination
Secondary Number of Subjects With Any and Grade 3 Solicited Local Symptoms Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = cry when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site. During the 4-day (Days 0-3) post-vaccination period
Secondary Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Solicited general symptoms assessed were fever [defined as rectal temperature =38.0 degrees Celsius (°C)], rash, meningism and parotid gland swelling. Any= incidence of the specified symptoms regardless of intensity grade or relationship to study vaccine. Grade 3 fever= rectal temperature above (>) 39.5°C. Grade 3 rash= more than 150 lesions. Grade 3 meningism and parotid gland swelling= meningism/parotid gland swelling symptom which prevented normal everyday activities. Related = general symptom assessed by the investigator as causally related to the vaccination. During the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects With Any Unsolicited Adverse Events (AEs) An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Within the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects With Serious Adverse Events (SAEs) Serious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. During the entire study period (from Day 0 up to Day 43 or Day 57)
See also
  Status Clinical Trial Phase
Completed NCT04183114 - Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Phase 2/Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT02196285 - Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella Phase 1
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00313950 - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Phase 4
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT01777529 - Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Phase 4
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT00109278 - A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) Phase 2
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT02880865 - Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Phase 4
Completed NCT01681992 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Phase 3
Completed NCT01702428 - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00388440 - Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Phase 4
Completed NCT03148990 - Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Phase 2/Phase 3